key: cord-0733697-5iorhx90 authors: Serpa Neto, Ary; Landoni, Giovanni; Ostermann, Marlies; Lumlertgul, Nuttha; Forni, Lui; Alvarez‐Belon, Lucas; Trapani, Tony; Alliegro, Patricia V.; Zacharowski, Kai; Wiedenbeck, Carolin; de Backer, Daniel; Bellomo, Rinaldo title: Angiotensin II infusion in COVID‐19: An international, multicenter, registry‐based study date: 2022-01-21 journal: J Med Virol DOI: 10.1002/jmv.27592 sha: 40063c663f502a929639b87023b9c03d8d03c416 doc_id: 733697 cord_uid: 5iorhx90 To expand our understanding of the role of angiotensin II (ANGII) in coronavirus infectious disease 2019 (COVID‐19), we conducted an international, multicenter registry study to assess the use of ANGII in patients with COVID‐19 compared to patients not receiving ANGII. Critically ill adult patients who were diagnosed with COVID‐19 and received ANGII were matched with COVID‐19 patients not receiving ANGII according to age, respiratory support, history of hypertension, use of angiotensin‐converting enzyme inhibitors and/or ANGII receptor blocker, and date of admission. All outcomes were exploratory in nature and included improvement in oxygenation, duration of organ support, and mortality. In one year, 132 patients were included (65 in the ANGII group and 67 in the control group), and patients were comparable in baseline characteristics. During the first 12 h of infusion, patients in the ANGII had a faster decrease in FiO(2) and maintained similar mean arterial pressure levels. Hospital mortality was not statistically significantly different between the groups (53.8% vs. 40.3%; p = 0.226). Within the limitations of such a study design, our findings confirm previous observations of a potentially positive effect of ANGII on blood pressure and FiO(2) but no effect on patient‐centered outcomes. Coronavirus infectious disease 2019 (COVID- 19) can cause severe acute respiratory syndrome requiring invasive mechanical ventilation. 1 Once ventilated, some patients develop vasodilatory hypotension and require vasopressor drugs. 2 Modulation of the renin-angiotensin-aldosterone system (RAAS) with vasopressor drugs may affect outcomes because the angiotensinconverting enzyme (ACE) type 2 is the viral receptor 3, 4 for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein and because drugs that inhibit the RAAS may affect the expression of ACE2 and, thereby, cell entry by the COVID-19 virus. 1, 5 Angiotensin II (ANGII) is a vasopressor approved by the United States Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of catecholamine-resistant vasodilatory shock 6 and a substrate for ACE2. In Phase III double-blind randomized trial, when used as rescue vasopressor, ANGII improved blood pressure in catecholamine-resistant vasodilatory shock. 7 Moreover, it increased survival in patients with a high ANGI/ANGII ratio 8 or a high renin level 9 and, in patients receiving renal replacement therapy (RRT) at randomization, it increased the likelihood of recovery to RRT independence. 10 In patients with COVID-19, the physiological effect of ANGII on oxygenation was recently assessed in an uncontrolled case series. This case series reported an improvement of PaO 2 /FiO 2 ratio with ANGII. 11 In contrast, more recently, a small case series reported that ANGII was associated with poor outcomes in six COVID-19 patients. 12 However, these observational assessments lacked controls. Finally, a single-center study reported increased blood pressure and PaO 2 /FiO 2 ratio, decreased risk of liver dysfunction, and, in patients with abnormal baseline serum creatinine, a suggestive decrease of RRT use. 13 Given such limited data and to expand our understanding of the role of ANGII in COVID-19-related hypotension, we conducted an international, multicenter registry study to assess the use of ANGII in patients with COVID-19 compared to patients not receiving ANGII across different centers in Europe. In particular, we aimed to test the hypothesis that ANGII would be associated with improved PaO 2 /FiO 2 ratios compared with controls as suggested by previous work. This is a prospective international, multicenter, ANGII registry-based study, including patient-centered outcomes. The study was approved by the Alfred Hospital Ethics Committee (Project Number 215/20) and in each local center according to local regulations. A waiver of consent was obtained. The study was registered on ANZCTR (ACTRN12620000620921) and on ClinicalTrials.gov (NCT04408326) and data from some patients from a single center component of this cohort was published previously. 11,13 Critically ill adult patients who were diagnosed with COVID-19 and received ANGII infusion were considered for inclusion. In addition, matched control patients were critically ill adults who were diagnosed with COVID-19 but did not receive ANGII infusion. The following additional inclusion criteria were considered for the identification of matched controls: 1) receiving vasopressor infusion; and 2) matched to a patient from the ANGII group by the following criteria: date of intensive care unit (ICU) admission (range of ±2 days), age (range of ±2 years), respiratory support at ICU admission (no supplemental oxygen or supplemental oxygen or noninvasive ventilation/high flow nasal cannula or invasive ventilation), history of hypertension, and use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs). No exclusion criterion was considered. Medical records were used for data collection. We obtained data on medical history, clinical and laboratory data every 6 h in the first 12 h after the start of the infusion of ANGII (ANGII group) or other vasopressors (in the control group). Daily data collection was restricted to the first 3 days after inclusion, and outcome data. All data were collected by trained investigators independent from the clinical teams. Before analysis, an extensive round of data cleaning was performed to check for data accuracy. All outcomes reported in this study are exploratory in nature. Note: Data are median (Quartile 25th-75th) and N/total (%). Abbreviations: ACE, angiotensin-converting enzyme; ARBs, angiotensin II receptor blockers; ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit; SOFA, sequential organ failure assessment. T controls at a similar time, the serum creatinine was higher in the ANGII group (Table 2) . During the first 12 h of infusion, patients in the ANGII had a faster decrease in FiO 2 (p = 0.039) and maintained similar mean arterial pressure levels ( Table 2 and Figure S1 ). PaO 2 / FiO 2 levels at 6 and 12 h were higher in patients in the ANGII group after 6 h of infusion, but all other laboratory tests remained unchanged (Table 2 and Figure S2 ). The effect on FiO 2 and PaO 2 / FiO 2 was maintained after adjustment for PEEP level and use of prone positioning (Table 2 ). During the first 3 days after inclusion, FiO 2 remained lower and mean arterial pressure higher in patients in ANGII group ( Figure S3 and Table S2 ). In addition, in the first 2 days, PaO 2 / FiO 2 were higher in patients in the ANGII group ( Figure 1 and Table S2 ). The effect on FiO 2 and PaO 2 /FiO 2 was maintained after adjustment for PEEP level and use of prone positioning (Table S2 ). Noradrenaline dose on Day 1 was higher in the ANGII group. In addition, the use of prone positioning on Day 1 and PEEP levels on Days 1 and 3 were also higher in the ANGII group (Table S2 ). All other laboratory tests were similar between the groups. Patients in the ANGII group received ANGII for a median of 5 (3-6) days. The need for RRT and ECMO during hospital stay was similar between the groups (Table 3) . Overall, prone positioning was used more often in patients in the ANGII group. The incidence of complications during a hospital stay, including stroke and acute myocardial infarction was similar between the groups. After adjustment for confounders, ventilator-free days at Day 28, ICU and hospital-free days at Day 28, and ICU and hospital mortality were similar between the groups (Table 3 and persisted even after adjustment for the higher PEEP levels and the more common use of prone positioning and was combined with a higher mean arterial pressure. Finally, after adjustment, ventilator, ICU and hospital-free days, and ICU and hospital mortality were not significantly different. Following the Angiotensin II for the Therapy in High Output Shock (ATHOS) trial, the United States FDA and EMA approved the use of ANGII infusion for the treatment of catecholamine-resistant (requiring ≥0.2 µg/kg/min of norepinephrine infusion) vasodilatory shock. 6 The median dose reported in our study is consistent with the ATHOS trial criteria for the use of ANGII. In the ATHOS trial mortality at 28 days was 48% for ANGII treated patients. Our observation of a 49% 60-day mortality is aligned with such findings. RRT, however, was used in approximately 26% of COVID-19 patients, a lower value than the near 33% seen in the ATHOS trial. 10 The apparent physiological effects on oxygenation observed in this study are in line with a recently reported case series in COVID-19 patients 11 and a single-center study of COVID-19 critically ill subjects. 13 The increase in blood pressure was expected and is also consistent with the ATHOS trial, postmarketing studies of ANGII, 14, 15 a recent case series on COVID-19 patients, 16 receptor. 17 Because of concern about the role of the ACE2 receptor in the cell to cell spread of the COVID-19 virus, several studies have also explored the role of either continuing or discontinuing ACEIs and angiotensin receptor blockers. Such studies have broadly found no detectable effect with either continuation or discontinuation of these medications. [18] [19] [20] Finally, it is unknown which vasopressor agent would be safest Our findings imply that, in a cohort of patients already receiving a median dose of approximately 0.2 µg/kg/min of norepinephrine, ANGII infusion increased blood pressure compared with controls. Moreover, this effect was associated with favorable changes in FiO 2 . However, there was no signal to suggest a beneficial effect on patient-centered outcomes. Note: Data are median (Quartile 25th-75th) and N/Total (%). Abbreviations: CI, confidence interval; ECMO, extracorporeal membrane oxygenation; HR, hazard ratio; ICU, intensive care unit; MD, median difference; RD, risk difference. a All models adjusted for diabetes, ventilatory support, SpO 2 , and noradrenaline dose at ICU admission, and considering the hospital of admission as a random effect. *p = 0.950 for Schoenfeld residuals. In conclusion, we report the findings of a registry-based casematched controlled assessment of ANGII treatment in COVID-19 patients receiving a high median dose of vasopressor therapy at baseline. Within the limitations of such a study design, our findings confirm previous observations of a potentially positive effect on blood pressure and FiO 2 but no effect on patient-centered outcomes. These observations suggest the need to obtain more controlled information on the use of other vasopressor agents in COVID-19 patients. Moreover, taken together with studies of ACEI and ARB, they provide further evidence that ACE2 receptor manipulation is unlikely to impact clinical outcomes in COVID-19 patients. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention Characteristics, treatment, outcomes and cause of death of invasively ventilated patients with COVID-19 ARDS in Clinical characteristics of coronavirus disease 2019 in China SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor Cryo-EM structure of the 2019-nCoV spike in the perfusion conformation COVID-19 and the RAAS-a potential role for angiotensin II? Angiotensin II for the treatment of vasodilatory shock Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock Renin and survival in patients given angiotensin II for catecholamine-resistant vasodilatory shock Outcomes in patients with vasodilatory shock and renal replacement therapy treated with intravenous angiotensin II Angiotensin II infusion in COVID19-associated vasodilatory shock: a case series Angiotenin II treamtent in COVID-19 patients: more risk than benefit? A single-center experience Angiotensin II infusion and markers of organ function in invasively ventilated COVID-19 patients Angiotensin II: a review of current literature Angiotensin II infusion for shock: a multicenter study of post-marketing use Angiotensin II administration in patients with COVID-19 shock Angiotensin-II mediates ACE2 internalization and degradation through an angiotensin-II type I receptor-dependent mechanism Effect of discontinuing vs continuing angiotensin converting enzyme inhibitors and angiotensin II receptor blockers on days alive and out of the hospital in patients admitted with COVID-19: a randomized controlled clinical trial Reninangiotensin aldosterone system inhibitors in primary prevention and CPVID-19 Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19: a prospective parallel group, randomized, controlled, open label trial Right ventricular dysfunction in patients with COVID-19: a systematic review and meta-analysis Vasopressor use in cardiogenic shock Vasopressin infusion in COVID-19 critical illness is not associated with impaired viral clearance: a pilot study How to cite this article: Serpa Neto A Angiotensin II infusion in COVID-19: an international, multicenter, registry-based study The authors declare that there are no conflict of interests. The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions. http://orcid.org/0000-0003-1520-9387 The peer review history for this article is available at https://publons. com/publon/10.1002/jmv.27592.